Kazia Therapeutics Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Edwin Friend
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Three International Towers Sydney NSW Australia 2000
- IPO Date
- Jan 6, 1999
- CIK
- 0001075880
- Website
- kaziatherapeutics.com
- Similar Companies
- Business
- Kazia Therapeutics Limited (NASDAQ: KZIA) is an Australian clinical-stage oncology-focused biotechnology company that develops novel small-molecule therapeutics targeting hard-to-treat cancers, including brain cancers and solid tumors; its lead product candidate is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway in development for glioblastoma, diffuse intrinsic pontine glioma, triple-negative breast cancer, and other solid tumors; EVT801, a selective VEGFR3 inhibitor licensed from Evotec SE, targets tumor angiogenesis and metastasis in advanced solid tumors; and the company recently in-licensed NDL2, a first-in-class PD-L1 protein degrader from QIMR Berghofer Medical Research Institute, for immuno-oncology applications. Founded in 2007 and headquartered in Sydney, Australia, Kazia operates primarily in Australia, Israel, and the United States, serving patient populations with high unmet needs in oncology through clinical-stage drug development programs conducted via partnerships with leading research institutions and contract research organizations. Recent developments include a $50 million private placement equity financing priced on December 2, 2025, expected to close on December 3, 2025, to fund advancement of paxalisib and other programs including the PD-L1 degrader; a collaboration and in-licensing agreement with QIMR Berghofer announced October 7, 2025, for the NDL2 PD-L1 degrader program; sale of all Cantrixil intellectual property and trademark rights to Vivesto AB for $1 million completed March 31, 2025; FDA alignment achieved in Q1 2025 on a pivotal Phase 3 study design for paxalisib in glioblastoma; and ongoing Phase 1b trials of paxalisib in combination therapies for metastatic triple-negative breast cancer alongside topline data anticipated from EVT801's Phase 1 trial in solid tumors.
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Short Interest in Novogen Limited (NASDAQ:KZIA) Decreases By 35.4%
Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
What's Going On With Cancer Firm Kazia Therapeutics
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market